Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Heather Ann Mcsharry Sells 2,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Heather Ann Mcsharry sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director owned 18,449 shares of the company’s stock, valued at $4,446,209. This trade represents a 9.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jazz Pharmaceuticals Stock Up 0.1%

JAZZ stock opened at $237.56 on Thursday. The firm has a 50 day moving average of $205.91 and a 200 day moving average of $182.44. The stock has a market capitalization of $14.90 billion, a PE ratio of -11,872.06, a price-to-earnings-growth ratio of 0.42 and a beta of 0.27. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals in the second quarter valued at $127,344,000. Goldentree Asset Management LP purchased a new position in Jazz Pharmaceuticals in the third quarter valued at $149,597,000. Franklin Resources Inc. increased its holdings in Jazz Pharmaceuticals by 164.0% in the fourth quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Jazz Pharmaceuticals by 160.2% in the fourth quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after buying an additional 715,361 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its holdings in Jazz Pharmaceuticals by 258.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock valued at $93,160,000 after buying an additional 395,000 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JAZZ. Sanford C. Bernstein began coverage on Jazz Pharmaceuticals in a research report on Thursday, May 21st. They issued a “market perform” rating and a $229.00 target price on the stock. Morgan Stanley restated an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Truist Financial upgraded shares of Jazz Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $242.65.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.